|Stage of funding:||Completed|
Founded in 2006 and located in Sunnyvale, California, Miramar Labs is a privately-owned medical device company dedicated to launching the next generation energy modality to treat dermatologic medical conditions.
Miramar Labs is the tenth company created by The Foundry, a leading medical device incubator based in Menlo Park, California.
Supported by rigorous clinical research, Miramar Labs is focused on addressing dermatologic medical conditions for which there are significant unmet clinical needs. Miramar Labs is excited to have developed its miraWave technology™, a breakthrough technology platform using microwave energy. Used for treatment in other medical areas such as oncology, cardiology and urology, microwave energy is well-positioned to be adopted for dermatologic conditions.
The first priority is the treatment of excessive axillary hyperhidrosis, a medical condition that significantly affects the quality of life of tens of millions of people. The miraDry procedure uses microwave energy to provide a non-invasive, lasting solution to axillary hyperhidrosis. The miraDry System available in North America, Europe and Asia Pacific for the treatment of primary axillary hyperhidrosis.
Miramar Labs, Inc. (OTCQB: MRLB) was acquired by Sientra, Inc. (NASDAQ: SIEN) in July 2017.
NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees. The study is being conducted with the Uniformed Services University of the Health Sciences (USU) and is enrolling U.S. Army Infantry trainees at Fort Benning, GA. NDV-3A is the company’s lead development candidate to potentially treat antimicrobial resistant fungal and bacterial pathogens.
12 April 2018
30 March 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
14 March 2018